Ghent University Hospital
Ghent, Belgium
25 recruiting
Showing 1–20 of 88 trials
Recruiting
Phase 1Phase 2
A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.
Shock, Cardiogenic
4TEEN4 Pharmaceuticals GmbH90 enrolled25 locationsNCT06832722
Recruiting
Phase 3
Vorasidenib Maintenance for IDH Mutant Astrocytoma
IDH-mutant Grade 2 or 3 Astrocytoma
European Organisation for Research and Treatment of Cancer - EORTC468 enrolled33 locationsNCT06809322
Recruiting
EORTC Metastatic Breast Cancer Module Development
Metastatic Beast Cancer
University of Leeds568 enrolledNCT07806266
Recruiting
Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled211 locationsNCT06982521
Recruiting
Phase 1Phase 2
Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy
Retinitis pigmentosa (RP)Rod-Cone Dystrophy
SparingVision27 enrolledNCT07807111
Recruiting
Not Applicable
Optimization of the Isolation Protocol for Extracellular Vesicles (EVs) From Human Follicular Fluid
Extracellular Vesicles
University Hospital, Ghent4 enrolled1 locationNCT06952751
Recruiting
Phase 2
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC480 enrolled203 locationsNCT06667076
Recruiting
Phase 3
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostatic Neoplasms
Janssen Research & Development, LLC1,203 enrolled172 locationsNCT07164443
Recruiting
Phase 2Phase 3
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Crohn Disease
Janssen Research & Development, LLC1,092 enrolled368 locationsNCT07196722
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Acute Leukemia
Janssen Research & Development, LLC420 enrolled102 locationsNCT04811560
Recruiting
Phase 3
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Crohn Disease
Janssen Research & Development, LLC460 enrolled55 locationsNCT07577843
Recruiting
Not Applicable
A Pivotal Study Evaluating Safety and Effectiveness of Adaptative Tip Catheter in Patients With Acute Ischemic Stroke
Ischemic Stroke
Neuravi Limited74 enrolled15 locationsNCT07367100
Recruiting
Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Multiple Myeloma
Janssen Research & Development, LLC1,590 enrolled270 locationsNCT05552222
Recruiting
Phase 3
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Crohn Disease
Janssen Research & Development, LLC530 enrolled144 locationsNCT07499232
Recruiting
Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Colitis Ulcerative
Janssen Research & Development, LLC882 enrolled400 locationsNCT07196748
Recruiting
Phase 3
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
Colitis Ulcerative
Janssen Research & Development, LLC644 enrolled63 locationsNCT07577856
Recruiting
Phase 3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC600 enrolled257 locationsNCT06852222
Recruiting
Phase 1
A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults
Healthy Volunteer
Regeneron Pharmaceuticals88 enrolledNCT07526116
Recruiting
Phase 2
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
CSL Behring84 enrolled99 locationsNCT07332091
Recruiting
Phase 2
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Advanced Breast CancerHormone Receptor-Positive Breast CarcinomaAdvanced Breast Carcinoma
MedSIR200 enrolled79 locationsNCT06486883